Market capitalization | $37.19m |
Enterprise Value | $29.84m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 13.50 |
P/S ratio (TTM) P/S ratio | 16.83 |
P/B ratio (TTM) P/B ratio | 7.57 |
Revenue growth (TTM) Revenue growth | 26.94% |
Revenue (TTM) Revenue | $2.21m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
3 Analysts have issued a Lumos Pharma Inc forecast:
3 Analysts have issued a Lumos Pharma Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 2.21 2.21 |
27%
27%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -36 -36 |
3%
3%
|
EBIT (Operating Income) EBIT | -36 -36 |
2%
2%
|
Net Profit | -35 -35 |
6%
6%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.
Head office | United States |
CEO | Richard Hawkins |
Employees | 33 |
Founded | 1999 |
Website | www.lumos-pharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.